The Phase I trial is a single center, open label study, designed to evaluate safety, distribution and dosimetry of BFPET as a PET tracer for myocardial perfusion imaging in healthy subjects. The study will be led by Alan Fischman, professor of radiology at Harvard Medical School and former director of the Nuclear Medicine Division at Massachusetts General Hospital.
Ljiljana Kundakovic, FluoroPharma’s president, said: “BFPET’s progress follows on the tail of CardioPET, an agent for the detection of metabolic integrity of the heart, which recently completed a Phase I safety evaluation in normal healthy volunteers and cardiac patients.”